ArticleRSC advances2026
Photopolymerized radiopaque composites for long-term imaging in transcatheter arterial embolization.
Xiujuan Ai, Qinglin Xiao, Wenyu Hong, Ting Wang, Xufeng Li, Mianrong Chen, Guodong Ye, Kedong Yuan
Abstract read
In one paragraphArticle in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Xiujuan AiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China gzhygd@gzhmu.edu.cn kedongyuan@gzhmu.edu.cn.
Qinglin XiaoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China gzhygd@gzhmu.edu.cn kedongyuan@gzhmu.edu.cn.
Wenyu HongGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China gzhygd@gzhmu.edu.cn kedongyuan@gzhmu.edu.cn.
Ting WangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China gzhygd@gzhmu.edu.cn kedongyuan@gzhmu.edu.cn.
Xufeng LiLaboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, The Second Affiliated Hospital, Guangzhou Medical University Guangzhou 510260 China mianrong@163.com.
Mianrong ChenLaboratory of Interventional Radiology, Department of Minimally Invasive Interventional Radiology and Interventional Cancer Center, The Second Affiliated Hospital, Guangzhou Medical University Guangzhou 510260 China mianrong@163.com.
Guodong YeGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China gzhygd@gzhmu.edu.cn kedongyuan@gzhmu.edu.cn.ORCID https://orcid.org/0000-0002-7202-0006 Kedong YuanGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University Guangzhou 511436 China gzhygd@gzhmu.edu.cn kedongyuan@gzhmu.edu.cn.ORCID https://orcid.org/0000-0001-9711-5629 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
To enhance embolization accuracy, we developed a novel radiopaque embolic agent consisting of poly(sucrose allyl ether) incorporated with tantalum nanoparticles. Ta@PSAE exhibited sustained CT visibility (∼1000 HU) over 21 days following renal artery embolization, along with excellent biocompatibility,
Identifiers
PMID42395701
PMCPMC13326674
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390